Form 4: Climb Bio Director Douglas E. Williams Acquires Stock Options

Director Douglas E. Williams reports acquisition of stock options in Climb Bio, Inc.

Summary

• Douglas E. Williams, a director of Climb Bio, Inc., filed a Form 4 indicating a transaction involving derivative securities.
• On March 31, 2025, Williams acquired stock options representing the right to buy 78,873 shares of Climb Bio's common stock at an exercise price of $1.22.
• These options vest in equal monthly installments starting November 8, 2024, and continue until the third anniversary of that date, contingent upon continued service.
• Following the reported transaction, Williams beneficially owns 78,873 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition. The director's confidence is a slight positive, but it's not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Form 4, stock options, derivative securities, beneficial ownership, CLYM, Climb Bio, director, Williams